Immune Therapeutics, Inc.
IMUN · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | -$0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | $0 | $0 | $0 | -$0 |
| % Margin | – | – | – | – |
| Net Income | $0 | $0 | $0 | -$0 |
| % Margin | – | – | – | – |
| EPS Diluted | 0 | 0 | -66,150 | -0.01 |
| % Growth | – | 100% | -661,499,900% | – |
| Operating Cash Flow | – | – | – | $0 |
| Capital Expenditures | – | – | – | $0 |
| Free Cash Flow | – | – | – | $0 |